We are live on ! Find out more
RLAY icon

Relay Therapeutics

172 hedge funds and large institutions have $1.1B invested in Relay Therapeutics in 2023 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 67 increasing their positions, 47 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

92% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 12

84% more call options, than puts

Call options by funds: $195K | Put options by funds: $106K

43% more repeat investments, than reductions

Existing positions increased: 67 | Existing positions reduced: 47

7% more funds holding

Funds holding: 161172 (+11)

0.23% less ownership

Funds ownership: 107.05%106.82% (-0.23%)

25% less funds holding in top 10

Funds holding in top 10: 43 (-1)

33% less capital invested

Capital invested by funds: $1.64B → $1.1B (-$541M)

Holders
172
Holders Change
+11
Holders Change %
+6.83%
% of All Funds
2.73%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
23
Increased
67
Reduced
47
Closed
12
Calls
$195K
Puts
$106K
Net Calls
+$89K
Net Calls Change
-$316K

RLAY Hedge Fund Activity: Q3 2023 in Review

172 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Relay Therapeutics (RLAY) for Q3 2023, worth a combined $1.1B — down 33% from $1.64B a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new RLAY positions and 12 closed out — a net gain of 11 holders — while 67 added to existing stakes and 47 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $14.8M. The largest seller was State Street, cutting an estimated $24.8M.

  • 172 institutional investors held Relay Therapeutics (RLAY) as of Q3 2023, up from 161 in Q2 2023.
  • Funds reported $1.1B of Relay Therapeutics stock for Q3 2023, down 33% quarter-over-quarter.
  • 23 funds opened new Relay Therapeutics positions in Q3 2023 and 12 closed out, a net change of +11 holders.
  • The largest Relay Therapeutics buyer in Q3 2023 was Citadel Advisors, an estimated $14.8M added.
  • The largest Relay Therapeutics seller in Q3 2023 was State Street, an estimated $24.8M sold.

Based on aggregated 13F filings for Q3 2023.